CIK 0001860782
TSVT 2seventy bio, Inc.
Insider trading from SEC Form 4. Last filing May 15, 2025.
In brief
2seventy bio, Inc. (TSVT) has 32 SEC Form 4 filings on file from 12 insiders, the latest filed on May 15, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
18 open-market trades have been scored at TSVT. The newest: Victoria Eatwell (Chief Financial Officer) sold $13k of stock on Mar 17, 2025, filed Mar 19, 2025, scored 37 (weak). The largest of the 18 shown: Kynam Global Healthcare Master Fund, LP (10% owner) sold $80M on Mar 11, 2025, scored 72 (notable). 4 insiders sold within 14 days of each other around Mar 17, 2025.
2 Form 144 notices of planned sales are on file, the latest filed Dec 13, 2024.
Last 90 days
Signals
Open-market buys and sells at 2seventy bio, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 37Weak | Victoria Eatwell Chief Financial Officer sell | $13k 2,592 shares | -1% | - | |
| 45Moderate | William D Baird III President and CEO sell | $25k 5,092 shares | -0% | - | |
| 15Weak | Jessica Snow Chief Operating Officer sell | $11k 2,298 shares | -1% | - | |
| 72Notable | Kynam Global Healthcare Master Fund, LP owner sell | $80M 16,238,047 shares | -273% | - | |
| 50Moderate | William D Baird III President and CEO sell | $95k 32,481 shares | -4% | - | |
| 37Weak | Victoria Eatwell Chief Financial Officer sell | $3,244 1,110 shares | -0% | - | |
| 43Moderate | Nick Leschly President and CEO sell | $255k 86,870 shares | -7% | - | |
| 10Weak | Jessica Snow See Remarks sell | $18k 6,300 shares | -4% | - | |
| 0Weak | Jessica Snow See Remarks sell | $7,393 2,287 shares | -1% | - | |
| 20Weak | Marcela V. Maus director sell | $13k 3,900 shares | -14% | - | |
| 32Weak | Casdin Capital, LLC director buy | $204k 40,000 shares | +2% | - | |
| 50Moderate | Casdin Capital, LLC director buy | $3.9M 777,377 shares | +66% | - | |
| 40Moderate | Nick Leschly President and CEO sell | $5,833 1,554 shares | -0% | - | |
| 30Weak | Philip D Gregory Chief Scientific Officer sell | $2,984 795 shares | -0% | - | |
| 35Weak | William D Baird III Chief Operating Officer sell | $5,180 1,380 shares | -1% | - | |
| 51Moderate | William D Baird III Chief Operating Officer sell | $130k 33,651 shares | -17% | - | |
| 40Moderate | Philip D Gregory Chief Scientific Officer sell | $99k 25,613 shares | -10% | - | |
| 54Moderate | Nick Leschly President and CEO sell | $280k 72,312 shares | -6% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 13, 2024 | JESSICA C SNOW Officer | 10,341 0.02% of outstanding | $35k | Dec 13, 2024 | $3,157 |
| Nov 18, 2024 | MARCELA MAUS Director | 3,900 0.01% of outstanding | $13k | Nov 18, 2024 | none |
Transactions
The newest 50 of 81 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 13, 2025 | Lin Wei director | DDisposition to issuer Common Stock | -17,583 | - | - | 15,267 | May 15, 2025 |
| May 13, 2025 | Denice Torres director | DDisposition to issuer Common Stock | -12,050 | - | - | 19,510 | May 15, 2025 |
| May 13, 2025 | Marcela V. Maus director | DDisposition to issuer Common Stock | -12,050 | - | - | 11,702 | May 15, 2025 |
| May 13, 2025 | Charles W. Newton director | DDisposition to issuer Common Stock | -17,092 | - | - | 5,533 | May 15, 2025 |
| May 13, 2025 | Casdin Capital, LLC director | UTender of shares Common Stock, par value $0.0001 per share | -22,625 | $5.00 | $113k | 0 | May 15, 2025 |
| May 13, 2025 | Nick Leschly President and CEO | DDisposition to issuer Common Stock | -335,964 | - | - | 897,642 | May 15, 2025 |
| May 13, 2025 | Victoria Eatwell Chief Financial Officer | DDisposition to issuer Common Stock | -401,111 | - | - | 43,276 | May 15, 2025 |
| May 13, 2025 | Jessica Snow Chief Operating Officer | DDisposition to issuer Common Stock | -247,230 | - | - | 11,064 | May 15, 2025 |
| May 13, 2025 | Sarah JS Glickman director | DDisposition to issuer Common Stock | -12,050 | - | - | 15,602 | May 15, 2025 |
| May 13, 2025 | William D Baird III President and CEO | DDisposition to issuer Common Stock | -1,002,825 | - | - | 118,209 | May 15, 2025 |
| May 13, 2025 | Casdin Capital, LLC director | UTender of shares Common Stock, par value $0.0001 per shareindirect: See footnote | -2,000,000 | $5.00 | $10M | 0 | May 15, 2025 |
| May 13, 2025 | Marcela V. Maus director | UTender of shares Common Stock | -11,702 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Nick Leschly President and CEO | UTender of shares Common Stock | -897,642 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Lin Wei director | UTender of shares Common Stock | -15,267 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Denice Torres director | UTender of shares Common Stock | -19,510 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Jessica Snow Chief Operating Officer | UTender of shares Common Stock | -11,064 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | William D Baird III President and CEO | UTender of shares Common Stock | -118,209 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Charles W. Newton director | UTender of shares Common Stock | -5,533 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Victoria Eatwell Chief Financial Officer | UTender of shares Common Stock | -43,276 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Sarah JS Glickman director | UTender of shares Common Stock | -15,602 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Nick Leschly President and CEO | UTender of shares Common Stockindirect: Nick Leschly 2001 Trust | -15,233 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Marcela V. Maus director | DDisposition to issuer Stock Options (Right to buy)derivative | -24,100 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Sarah JS Glickman director | DDisposition to issuer Stock Options (Right to buy)derivative | -24,100 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Lin Wei director | DDisposition to issuer Stock Options (Right to buy)derivative | -24,100 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Denice Torres director | DDisposition to issuer Stock Options (Right to buy)derivative | -24,100 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Jessica Snow Chief Operating Officer | DDisposition to issuer Stock Options (Right to buy)derivative | -18,300 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Casdin Capital, LLC director | DDisposition to issuer Stock Options (Right to buy)derivative | -12,050 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Victoria Eatwell Chief Financial Officer | DDisposition to issuer Stock Options (Right to buy)derivative | -21,700 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Charles W. Newton director | DDisposition to issuer Stock Options (Right to buy)derivative | -33,400 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | William D Baird III President and CEO | DDisposition to issuer Stock Options (Right to buy)derivative | -182,000 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | William D Baird III President and CEO | DDisposition to issuer Stock Options (Right to buy)derivative | -176,000 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Nick Leschly President and CEO | UTender of shares Common Stockindirect: Nick Leschly Irrevocable GST Trust of 2019 | -41,000 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Casdin Capital, LLC director | DDisposition to issuer Stock Options (Right to buy)derivative | -33,400 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Jessica Snow Chief Operating Officer | DDisposition to issuer Stock Options (Right to buy)derivative | -70,750 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Victoria Eatwell Chief Financial Officer | DDisposition to issuer Stock Options (Right to buy)derivative | -18,300 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Charles W. Newton director | DDisposition to issuer Stock Options (Right to buy)derivative | -12,050 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Nick Leschly President and CEO | DDisposition to issuer Stock Options (Right to buy)derivative | -469,000 | - | - | 0 | May 15, 2025 |
| May 13, 2025 | Victoria Eatwell Chief Financial Officer | DDisposition to issuer Stock Options (Right to buy)derivative | -72,000 | - | - | 0 | May 15, 2025 |
| Mar 17, 2025 | Victoria Eatwell Chief Financial Officer | SOpen-market sale Common Stock | -2,592 | $4.95 | $13k | 444,387 | Mar 19, 2025 |
| Mar 17, 2025 | William D Baird III President and CEO | SOpen-market sale Common Stock | -5,092 | $4.95 | $25k | 1,121,034 | Mar 19, 2025 |
| Mar 17, 2025 | Jessica Snow Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -2,298 | $4.95 | $11k | 254,193 | Mar 19, 2025 |
| Mar 11, 2025 | Kynam Global Healthcare Master Fund, LP owner | SOpen-market sale Common Stock, par value $0.0001 per shareindirect: See Footnote | -5,953,825 | $4.93 | $29M | 0 | Mar 13, 2025 |
| Mar 11, 2025 | Kynam Global Healthcare Master Fund, LP owner | SOpen-market sale Common Stock, par value $0.0001 per share | -5,142,111 | $4.93 | $25M | 0 | Mar 13, 2025 |
| Mar 11, 2025 | Kynam Global Healthcare Master Fund, LP owner | SOpen-market sale Common Stock, par value $0.0001 per shareindirect: See Footnote | -5,142,111 | $4.93 | $25M | 0 | Mar 13, 2025 |
| Jan 6, 2025 | Jessica Snow See Remarks | AGrant or award Common Stock | +106,150 | $0.00 | $0 | 253,329 | Jan 8, 2025 |
| Jan 6, 2025 | Victoria Eatwell Chief Financial Officer | AGrant or award Common Stock | +108,000 | $0.00 | $0 | 446,979 | Jan 8, 2025 |
| Jan 6, 2025 | William D Baird III President and CEO | AGrant or award Common Stock | +264,000 | $0.00 | $0 | 1,126,126 | Jan 8, 2025 |
| Jan 6, 2025 | Jessica Snow See Remarks | AGrant or award Stock Option (Right to buy)derivative | +70,750 | $0.00 | $0 | 70,750 | Jan 8, 2025 |
| Jan 6, 2025 | Victoria Eatwell Chief Financial Officer | AGrant or award Stock Option (Right to buy)derivative | +72,000 | $0.00 | $0 | 72,000 | Jan 8, 2025 |
| Jan 6, 2025 | William D Baird III President and CEO | AGrant or award Stock Option (Right to buy)derivative | +176,000 | $0.00 | $0 | 176,000 | Jan 8, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- William D Baird IIIChief Operating Officer
- Casdin Capital, LLCdirector, owner
- Victoria EatwellChief Financial Officer
- Sarah JS Glickmancfo, officer, director
- Philip D GregoryChief Scientific Officer
- Kynam Global Healthcare Master Fund, LPowner
- Nick LeschlyPresident and CEO
- Marcela V. Mausdirector
- Charles W. Newtondirector, cfo, officer
- Jessica SnowChief Operating Officer
- Denice Torresdirector
- Lin Weidirector, officer
Questions about TSVT
Answered from the filings on this page, as of the latest one.
Are insiders buying TSVT?
No. In the last 90 days no insider at 2seventy bio, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade TSVT on the open market?
Victoria Eatwell (Chief Financial Officer) sold $13k of TSVT on Mar 17, 2025 and filed the Form 4 on Mar 19, 2025. InsiderTell scored 37 (weak), with 4 insiders on the same side within 14 days.
How many insiders file Form 4 at 2seventy bio, Inc.?
12 people have filed a Form 4 at 2seventy bio, Inc., among them William D Baird III (Chief Operating Officer), Casdin Capital, LLC (director and 10% owner), Victoria Eatwell (Chief Financial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.